Cherubic Ventures — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesSaaSNew York, US
Ben Liu(CEO & Co-Founder)inLinhao Zhang(Co-Founder)inBenjamine Liu(Founder)Kit Dobyns(Founder)Mary Rozenman(Founder)
BoardAlfred Lin(Director)in
Co-investorsAndreessen HorowitzSequoia CapitalSam AltmanSection 32Thrive CapitalFelicis Ventures+11 more
ResistanceBio develops treatments to address drug resistance in cancer patients.
BiotechHealthtechSan Francisco, US
Nicholas Goldner(CEO)inChristopher Bulow(Founder)inKYLE LAPHAM(Executive Officer, Director)
BoardOMRI AMIRAV-DRORY(Director)in
Co-investorsAlumni VenturesFifty YearsY CombinatorAsymmetry VenturesBrightstone Venture CapitalCantos Ventures+11 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Beaubble
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.










